AstraZeneca's late-stage trial results for breast cancer drug Datroway and label extensions for Enhertu and baxdrostat are expected to impact sales, targeting $80 billion by 2030.
Berenberg maintains a buy rating on AstraZeneca, targeting 140 pounds. Key 2025 catalysts include an oral PCSK9 drug with $10 billion sales potential and baxdrostat for hypertension at $6 billion.
AIM ImmunoTech has started a Phase 2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, aiming to enroll 25 patients.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.